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Abstract
With the increasing incidence of human cancer and continued difficulty in treating
metastatic tumors, there is an urgent need to identify biomarkers for tumors with poor
outcome and novel therapeutic targets. Many therapeutic targets have been found in
recent years. One promising biomarker and therapeutic target that is valuable for human
tumor is nuclear factor erythroid 2-related factor 2 (NFE2L2, Nrf2). In this chapter, we
will discuss the regulatory mechanisms and conflicting roles of Nrf2 during different
stages of tumor development as well as its involvement in the drug resistance and
hypoxia-induced chemoresistance. We will also discuss various positive and negative
modulators of Nrf2 as reference to their potential utility as study tools and leads for
further clinical development.
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1. Introduction
Nrf2 is the main regulator for the expression of antioxidant enzymes and the detoxification
proteins.  With these  abilities  of  Nrf2,  Nrf2  activation confers  cells  with more anti-stress
capacity, thus resulting in more malignancy and chemoresistance of tumor cells. Therefore,
targeting Nrf2 in tumor may offer therapeutic benefit by undermining its advantage on the
proliferation, migration, metastasis, and drug resistance of tumor cells. Collectively, Nrf2 has
the potential  to serve as a good biomarker and therapeutic target to overcome the poor
prognosis and chemoresistance associated with tumor or tumor hypoxia [1, 2].
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2. Nrf2 is the key regulator of antioxidant and detoxification abilities
Organisms survive based on the normal and steady function of cell metabolism to maintain
cellular homeostasis. However, the process of metabolism produces many metabolic wastes.
If these wastes are not properly removed, they become harmful. One of these metabolic wastes
is the reactive oxygen species (ROS). While ROS can serve the signaling function, uncontrolled
ROS may lead to cellular damage and death. Many key enzymes involved in the removal of
excess ROS are tightly regulated by a transcription factor, Nrf2.
Nrf2 activation is strictly regulated by an ubiquitin-proteosome system (UPS) [3]. Nrf2 is
negatively regulated by Keap1 (Kelch-like ECH-associated protein 1), the most important
molecular switch controlling the activation and inactivation of the Nrf2 pathway. Keap1 is an
adaptor for Nrf2 as the Nrf2-Keap1 complex becomes a substrate for the Cul3-dependent E3
ubiquitin ligase for proteasomal degradation. Keap1 is a cysteine-rich protein, which can be
modified by many oxidants and electrophiles. Upon exposure to oxidative stress, these cysteine
residues may be altered by stresses to induce conformational changes that inhibit Keap1-
dependent ubiquitin ligase activity to allow Nrf2 accumulation [4, 5].
Since Nrf2 is a transcription factor, the accumulated Nrf2 proteins translocate into the nucleus
to dimerize with members of the small Maf family, and bind to the antioxidant response
element (ARE or electrophile response element 5′-RTGABNNNGCR-3′) in the promoter
regions of cell defense genes [6]. These Nrf2-regulated proteins include Phase II detoxification
enzymes and some stress response proteins as listed below:
1. Antioxidant proteins: proteins that control the antioxidant specializing in neutralizing the
reactive species and protecting organisms from oxidative damage, such as NAD(P)H:
quinone oxidoreductase 1 (NQO1), epoxide hydrolase, heme oxygenase 1 (HO-1),
glutathione S-transferase (GST), and glutathione peroxidase (GPx).
2. Glutathione producing enzymes: proteins that regulate the synthesis and metabolism of
glutathione, such as glutamate-cysteine ligase (GCL), which consists of two subunits, a
light regulatory subunit; glutamate-cysteine ligase modifier subunit (GCLM), and a heavy
catalytic enzyme; GCL catalytic subunit (GCLC).
3. Drug-metabolizing enzymes: enzymes that regulate the metabolism of drugs, including
UDP-glucuronosyl-transferase 1A1 (UGT1A), carbonyl reductase 1 (CBR1), aldo-keto
reductases (AKR), and cytochrome P450 (CYPs).
4. Xenobiotic transporters (ATP-binding cassette (ABC) transporter): proteins that belong to
ATP phosphohydrolase, some of them are involved in the exclusion of drugs, xenobiotics
and their metabolites [7], which are named multidrug resistance proteins, such as
multidrug resistance protein 1 (MRP1).
5. Numerous other stress response proteins, such as thioredoxin, ferritin subunits, and
copper/zinc superoxide dismutase [8] (see Figure 1).
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Figure 1. Regulation of Nrf2. Keap1 binds to Nrf2 and sends it to proteasomal degradation. ROS can lead to the confor-
mational change of Keap1 and Nrf2 release. Free Nrf2 then enters the nucleus and initiate the following transcriptional
process by binding to the ARE domains, P21 and P62.
3. The conflicting roles of Nrf2
Since Nrf2 is the key regulator of antioxidant capacity and detoxified proteins, the activation
of Nrf2 is expected to protect cells from stresses, such as reactive oxygen species (ROS).
Therefore, the Nrf2 pathway is so called oxidative stress response pathway or cellular defense
pathway. Once cells or organisms are exposed to ROS induced by physical forces or chemicals,
Nrf2 is activated to increase the anti-stress capacity and cope with the ROS. Nrf2 activation
can stabilize the intracellular oxidant level and maintain the redox state within cells to avoid
DNA damages, genomic instability, and potentially serious sabotages caused by ROS [9].
Although DNA repair mechanism can reduce slight DNA damage, higher presence of
oxidizing base lesions in DNA leads to DNA mutation, which may cause aging [10], cell
damage, cell death, carcinogenesis, and even cancer. Therefore, various Nrf2 activators are
being pursued in chemopreventive strategies [11] to reduce tumor development. In addition,
Nrf2 activators have been used to treat various human diseases, including diabetic nephrop-
athy [12, 13] and sickle cell disease [14].
On the other hand, excess ROS may lead to numerous diseases, such as inflammation, obesity,
and other metabolic diseases. For example, too much oxidative stress affects the differentiation
of adipocytes and impairs the normal function of white adipose tissue [15], leading to
inflammation and adipokine secretion that affect the whole organism [16, 17]. The activation
of Nrf2 defense pathway can protect organisms from many metabolic diseases.
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Therefore, Nrf2 can be the double edged sword in the organism. In normal cells, Nrf2 activation
keeps the redox homeostasis and prevents cancer development. However, once cancer cells
have established, Nrf2 activation may drive oncogenesis and confer chemoresistance. In many
cancers, constitutive Nrf2 activation is an oncogenic mutation [18] and a biomarker for poor
prognosis [19, 20] (Figure 2). In the TCGA data, mutations in the Nrf2 pathways constitute one
of the major oncogenic pathways of lung cancers [21, 22]. The angel and devil roles of Nrf2 are
discussed in the following sections.
Figure 2. Nrf2 produces phase II enzymes that provide cell defense system, such as the antioxidant and detoxification,
in normal cells. Once tumor is formed and cancer cells get the cytoprotective abilities of Nrf2, which triggers anabolic
metabolic reprogramming, drug resistance, and stress adaption, Nrf2 leads to poor prognosis in patients.
4. The good side of Nrf2
Nrf2 activation in normal cells makes cells stronger against environmental stresses and
prevents carcinogenesis. Nrf2 is able to augment a wide range of cell defense processes, thereby
enhancing the overall capacity of cells to detoxify potentially harmful entities. As such, the
Keap1-Nrf2 pathway is generally considered as the major cellular defense pathway that offers
survival advantages.
Keap1-Nrf2 is the key cellular defense mechanism to combat oxidative stress. The activated
Nrf2 protect organisms from these diseases by diminishing the ROS. Nrf2 is such a natural
cytoprotective response against oxidative stress-induced inflammation. Nrf2-null mice tend
to spontaneously develop various inflammatory disorders, including glomerulonephritis [23],
immune-mediated hemolytic anemia [24], and multiorgan autoimmune inflammation [25].
Also, activated Nrf2 protects many body systems, including airway, liver, gastrointestinal tract
and kidney, where these systems are attacked by toxic agents very often [26]. For example,
Nrf2 activation via sulforaphane (Nrf2 inducer) protects kidney from chronic renal disease [27]
by increasing the GCLC and glutathione level. Activation of Nrf2 also alleviates the TGF-β-
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induced, increased α-SMA and repressed E-cadherin [28], which are the markers for epithelial-
mesenchymal transition (EMT), through the SMUR1-SMAD7 signaling. Another Nrf2 inducer,
AST120, can restore the HO-1 and NQO1 levels and decrease the production of ROS stimulated
by indoxyl sulfate-induced chronic renal disease [29] Nrf2 not only protects the kidney but
also protects the lungs. Nrf2 protects lungs from chronic pulmonary injury [30], fibrosis [31],
and acute lung injury [32, 33]. Therefore, Nrf2 is named as the “multiorgan protector” [34].
With cytoprotective functions and the cellular defense mechanism against exogenous and
endogenous insults, Nrf2 is considered as a tumor suppressor. In one hand, in vivo tumor
development data using Nrf2-knockout mice has highlighted the tumor suppression ability of
Nrf2. With treatment of chemical and physical stimuli, Nrf2-null mice are more prone to
develop cancer [35]. On the other hand, Nrf2 activation can remove damaged proteins,
promoting the overall survival of the cell and detoxify the cellular environment to maintain
the homeostasis in the organism [36]. The abilities of Nrf2 to combat oxidative stress and
inflammation, which are conducive to initiate oncogenesis, attain a result of tumor suppres-
sion [36].
5. The dark side of Nrf2
Gain of Nrf2 in cancer cells: the Nrf2 pathway is a powerful sensor for cellular redox state and
is activated directly by oxidative stress and/or indirectly by stress response protein kinases.
Although Nrf2 is beneficial to normal cells to fight against stresses, once tumor cells get the
antioxidant and detoxificative abilities of Nrf2, things go in another direction. For example,
the constitutive Nrf2 activation has redirected tumor metabolism to support the biosynthetic
needs of tumor proliferation [37, 38]. In addition, Nrf2 makes cancer cells stronger against
chemotherapy and leads cells to become more malignant. In this case, Nrf2 serves as a target
for chemotherapy. Recent researches have highlighted that persistent accumulation of Nrf2 in
cancer cells is harmful, since it can promote the survival and proliferation of cells that have
acquired cancer-promoting mutations, and Nrf2 is also observed beneficial for tumorigenesis
[11, 39–42]. Nrf2 orchestrates the expression of various genes that help cancer cells to resist
chemotherapeutic treatment, including antioxidants (NQO1, NQO2, HO-1, and GCLC),
antiapoptotic (Bcl-2), drug-metabolizing enzymes (G6PD, TKT, and PPARγ), and drug efflux
transporters (ABCG2, MRP3, and MRP4) genes [43].
The activation of Nrf2-ARE pathway protects cancer cells from oxidative toxicity and H2O2-
induced apoptosis [44, 45]. The effects of Nrf2 on tumors or cancer cells are listed below:
A. Proliferation, tumorigenesis and poor patient survival: Nrf2 contributes to the tumori-
genesis, cancer proliferation in bench and poor patient survival in clinic in various tumors,
including hepatocarcinoma (HCC) [46], breast tumor [47], nonsmall cell lung cancer
(NSCLC) [48], glioma [49, 50], pancreatic adenocarcinoma [51], and gastric cancer [52].
Nrf2 is also found to involve in the maintenance of quiescence, survival, and stress
resistance of cancer stem cells (CSCs), thus dedicating to tumor progression and recur-
rence [53].
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B. Chemotherapeutic resistance: Nrf2 exerts the detoxification and drug export through
activating multidrug resistance proteins and drug transporters. This action protects cancer
cells from the damage of chemotherapy, such as 5-fluorouracil (5-FU) in gastric cancer [54]
and in gallbladder cancer [55], and cisplatin (CDDP) and camptothecin in pancreatic
cancer [56].
C. Epithelial-mesenchymal transition (EMT), tumor metastasis, and malignancy: cancer cells
respond to some anti-diabetic drugs, which have antioxidant properties and inhibit the
Kea1-dependent obstruction of Nrf2, with Nrf2 activation and result in increased migra-
tion and metastasis, such as hypoglycemic dipeptidyl peptidase-4 inhibitors (DPP-4i),
saxagliptin and sitagliptin [57].
D. Hypoxia-induced drug resistance: Nrf2 contributes to the chemotherapeutic drug
resistance induced by hypoxia in breast cancers [2]. Hypoxia is a natural status in the
tumor center where the cancer cells outgrow the perfusion from local blood vessels for
getting enough oxygen and nutrients. Hypoxia triggers the ROS unbalance and stimulates
the activation of Nrf2 [2]. Following the Nrf2 nuclear translocation and ARE binding,
antioxidant enzymes are produced to maintain the stability of intracellular redox state.
Blocking ROS unbalance by ROS scavenger inhibits the Nrf2 activation and the following
drug resistance. Inhibition of Nrf2 or the production of related enzymes with siRNA or
specific inhibitor blocks the chemoresistance under hypoxia (Figure 3).
Figure 3. Nrf2, activated by hypoxia-induced ROS unbalance, starts the production of protective enzymes and contrib-
utes to the hypoxia-related chemoresistance. Specific inhibitors or siRNA targeting Nrf2 or downstream enzymes in-
creases the cytotoxic effects of chemotherapeutic drugs.
6. Nrf2 activation in tumors
Nrf2 gets activated in malignant tumors, such as carcinomas of skin, lung, oesophagus, and
larynx [58]. Many factors control the activation of Nrf2 in tumors, some are listed below.
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a. The somatic mutation of Keap1 or Nrf2: the mutations in Keap1 or Nrf2 hurt the interaction
of Keap1 and Nrf2, leading to a higher free Nrf2 level and activity [59].
b. The decreased level of Keap1: besides somatic mutations of Keap1, epigenetic changes,
such as hypermethylation on the promoter region of Keap1, decrease the expression level
of Keap1 [60]. In addition, several studies have shown that miRNAs, including mir-200A
[61, 62], miR-141 [63] and mir-28 [64], also regulates the expression level of Keap1 mRNA.
These events lead to the decreased level of Keap1 and the nuclear accumulation of Nrf2.
c. The increased level of Nrf2: Nrf2 can be activated by increase of some oncogenes, such
as KrasG12D [42], or disruption of tumor suppressors, such as PTEN [37] in tumors, that
lead to better cell survival and higher drug resistance.
d. Nrf2 polymorphism: in addition to varying Nrf2 expression, Nrf2 polymorphism also
affects the Nrf2 activity. The Nrf2 polymorphism contributes to poor prognosis in cancers,
including cholangiocarcinoma [65], lung cancer [66], and breast cancer [67]. It also
contributed to diseases, such as increasing the risk of acute lung injury [68, 69] as well as
blood pressure and cardiovascular mortality in patients with hemodialysis [70].
7. Regulators of Nrf2
Many molecules and chemicals are thought to regulate the Nrf2 activation; some of them are
described as following (see Figure 4):
A. Negative regulators:
♦ Endogenous
a. Keap1: Keap1 is a natural intracellular molecule that negatively regulates the
activation of Nrf2. Keap1 binds to Nrf2 in the cytoplasm, sends Nrf2 to proteosome
digestion, and keeps a low Nrf2 level in cells.
b. Ubiquitin-specific processing protease 15 (USP15): USP15 deubiquitinates Keap1,
stabilizes the Keap1-Cul3-E3 ligase complex, and enhances the E3 ligase activity,
which leads to the binding between Keap1 and Nrf2 and the degradation of Nrf2
[71].
♦ Exogenous
c. Trigonelline: trigonelline is a coffee alkaloids that reduce nuclear accumulation of
the Nrf2 protein, block expression of proteasomal genes (for example, s5a/psmd4
and α5/psma5), and reduce proteasome activity regulated by Nrf2 [72].
d. Vitamin C (ascorbic acid) [73, 74] and Vitamin E [75]: these two vitamins are water
soluble vitamins with a high capacity to capture ROS. Since Nrf2 is activated via
ROS imbalance, elimination of ROS by vitamins keeps low intracellular ROS and
ends in low Nrf2 activity.
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e. ROS scavenger: ROS scavenger is a common name for molecules that can balance
the intracellular ROS, including dithiothreitol (DTT) [76], N-acetylcysteine (NAC)
[77], catalase [78], 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid
(Trolox) [75]. They are used as standards to check the antioxidant capacity of other
molecules. Nrf2 activity remains low where these ROS scavengers keep the
intracellular ROS level steady.
f. Brusatol: Brusatol is a quassinoid that provokes a rapid and transient inhibition of




a. ROS: ROS imbalance is the key regulator of Nrf2. Excess ROS induces the activation
and nuclear translocation of Nrf2 to keep intracellular ROS balance through
upregulating the level and activity of antioxidant enzymes.
b. Hypoxia: hypoxia or lack of oxygen is a prominent tumor environmental stress,
and reported to induce ROS unbalance that is subsequently leading to Nrf2
activation [2, 82, 83].
♦ Disruptor proteins and transcription factors
c. P21 and p62: in addition to the conformational change of Keap1 to loss the bonding
affinity to Nrf2, some proteins, such as p21 and p62, can directly bond to Keap1 or
Nrf2, disrupting the interaction between Nrf2 and Keap1, thus ending in the
nuclear accumulation and activation of Nrf2 [84–86].
d. AhR: Aryl hydrocarbon receptor (AhR), which is a ligand-dependent transcrip-
tion factor by forming a heterodimer with the aryl hydrocarbon nuclear
translocator (Arnt) as a nuclear partner protein. The heterodimeric protein
complex regulates expression of Nrf2, and promotes the expression of phase I
enzymes, phase II enzymes, and multidrug resistance-associated proteins [87–
90]. Nrf2 can also regulate the activation of AhR and subsequently modulates
downstream AhR signaling cascades, including increasing the expression of
xenobiotic metabolism genes and inhibit the adipogenesis in mouse embryonic
fibroblasts (MEFs) [91].
e. Ebselen: ebselen is a glutathione peroxidase-1 mimetic and a seleno-organic
antioxidant. It attenuated cisplatin-induced oxidative stress generation through
Nrf2 pathway [92].
♦ Natural products or extracts
f. Sulforaphane (SFN): sulforaphane, which is found in cruciferous vegetables,
belongs to the isothiocyanate family (such as broccoli) and is widely used as an
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antioxidant supplement and applied in cancer chemoprevention [93]. SFN reacts
with Keap1 and block the binding of Keap1 and Nrf2, thus activates Nrf2 and the
antioxidant function [94].
g. Curcumin: curcumin, which is a polyphenolic natural extract of turmeric [95], is
reported to exhibit anti-inflammation and antitumorigenic activity and chemo-
prevention effect [96, 97]. To activate those protective proteins, curcumin increase
the antioxidant genes through regulating the binding of Nrf2 and ARE [98, 99].
Thus, curcumin becomes one of the Nrf2 activator.
h. Resveratrol: in addition to curcumin, resveratrol is another plant extract that
regulates antioxidant ability. Resveratrol, the extract from grapes, berries and
peanuts, exerts antioxidant, anti-inflammation, and anti-aging effects in experi-
mental animals. Resveratrol is also reported to upregulate Nrf2 activity in cells
and organisms to elevate the protection effects toward environmental stresses
[100].
i. Coffee: coffee is one of the most widely consumed beverages in the world. Coffee
is noted for its antioxidant ability which protects against chronic liver disease,
diabetes, and hepatocarcinoma development with the right amount. The antioxi-
dant ability of coffee is through the activation of Nrf2 and AhR to protect organs
from oxidative stress, at least in liver and stomach [101].
j. Caffeic acid phenethyl ester (CAPE): CAPE, a major component extracted from the
bee product propolis in honeybee hives, is known to have antimitogenic, anticar-
cinogenic, anti-inflammatory activities. It activates the Nrf2 pathway to inhibit
oxidative stress and inflammation [102].
k. Cinnamic aldehyde: cinnamic aldehyde, which is found in cinnamon bark,
enhances Nrf2 nuclear translocation and activates Nrf2 -dependent antioxidant
response to overcome stresses [103, 104].
l. Flavonoid (Chrysin, Apigenin, Luteolin): these three flavonoids can reduce the
ROS level through activating Nrf2 and producing the downstream phase II
enzymes [105].
♦ Synthesized compounds
m. Oltipraz: oltipraz is an organosulfur compound belonging to the dithiolethione
class. It is also a bifunctional inducer activating both phase I and phase II drug-
metabolizing enzymes via the xenobiotic responsive element [106]. It has been used
as an Nrf2 activator in recent studies [107, 108].
n. Tertiary butylhydroquinone (tBHQ): tBHQ, the major metabolite of butylated
hydroxyanisole, stabilizes Nrf2 and induces Nrf2 activation through mitochondri-
al oxidative stress induction [109, 110].
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o. Other food and clinical drugs: many other foods or clinical drugs can also affect
the expression and activity of Nrf2 in recent studies.
Figure 4. Positive and negative regulators of Nrf2, and the functions of enzymes and proteins produced by Nrf2 activa-
tion.
8. Conclusion
Nrf2 is powerful in the cell defense system toward oxidative stress caused by various physio-
logical and chemical stresses. Nrf2 activation benefits the survival of not only normal cells but
also cancer cells. With the anti-oxidation and detoxification abilities of Nrf2, the proliferation,
tumorigenicity, migration, and metastasis of cancer cells are higher. The detoxification and
drug export mechanism also give cancer cells the ability to fight against chemotherapeutic
drugs. With all the characteristics of Nrf2, it is a good marker for both poor prognosis and drug
resistance in tumors, both in the regular normoxic environment or under hypoxic environ-
ment [111].
Author details
Jhih-Pu Syu1, Jen-Tsan Chi2,3 and Hsiu-Ni Kung1*
*Address all correspondence to: kunghsiuni@gmail.com
1 Department of Anatomy and Cell Biology, College of Medicine, National Taiwan University,
Taipei, Taiwan
2 Center for Genomic and Computational Biology, Duke University, Durham, NC, USA
3 Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA
A Master Regulator of Oxidative Stress - The Transcription Factor Nrf2102
References
[1] Zhang, M., Zhang, C., Zhang, L., Yang, Q., Zhou, S., Wen, Q., and Wang, J. (2015) Nrf2
is a potential prognostic marker and promotes proliferation and invasion in human
hepatocellular carcinoma. BMC Cancer 15, 531.
[2] Syu, J. P., Chi, J. T., and Kung, H. N. (2016) Nrf2 is the key to chemotherapy resistance
in MCF7 breast cancer cells under hypoxia. Oncotarget 7, 14659–14672.
[3] Chapple, S. J., Siow, R. C., and Mann, G. E. (2012) Crosstalk between Nrf2 and the
proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging. Int J
Biochem Cell Biol 44, 1315–1320.
[4] Canning, P., Sorrell, F. J., and Bullock, A. N. (2015) Structural basis of Keap1 interactions
with Nrf2. Free Radic Biol Med 88, 101–107.
[5] Vriend, J., and Reiter, R. J. (2015) The Keap1-Nrf2-antioxidant response element
pathway: a review of its regulation by melatonin and the proteasome. Mol Cell Endo‐
crinol 401, 213–220.
[6] Lacher, S. E., Lee, J. S., Wang, X., Campbell, M. R., Bell, D. A., and Slattery, M. (2015)
Beyond antioxidant genes in the ancient Nrf2 regulatory network. Free Radic Biol Med
88, 452–465.
[7] Dean, M., Hamon, Y., and Chimini, G. (2001) The human ATP-binding cassette (ABC)
transporter superfamily. J Lipid Res 42, 1007–1017.
[8] Zhang, Y., and Gordon, G. B. (2004) A strategy for cancer prevention: stimulation of the
Nrf2-ARE signaling pathway. Mol Cancer Ther 3, 885–893.
[9] Cooke, M. S., Evans, M. D., Dizdaroglu, M., and Lunec, J. (2003) Oxidative DNA
damage: mechanisms, mutation, and disease. FASEB J 17, 1195–1214.
[10] Harman, D. (1956) Aging: a theory based on free radical and radiation chemistry. J
Gerontol 11, 298–300.
[11] Kensler, T. W., and Wakabayashi, N. (2010) Nrf2: friend or foe for chemoprevention?
Carcinogenesis 31, 90–99.
[12] Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth,
M., Ruiz, S., Audhya, P., Christ-Schmidt, H., Wittes, J., Warnock, D. G., and Investiga-
tors, B. S. (2011) Bardoxolone methyl and kidney function in CKD with type 2 diabetes.
N Engl J Med 365, 327–336.
[13] de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G. L., Chin, M., Christ-Schmidt, H.,
Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H. J., McMurray, J. J.,
Meyer, C. J., Parving, H. H., Remuzzi, G., Toto, R. D., Vaziri, N. D., Wanner, C., Wittes,
J., Wrolstad, D., Chertow, G. M., and Investigators, B. T. (2013) Bardoxolone methyl in
type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369, 2492–2503.
Nrf2 Contributes to the Poor Prognosis and Chemoresistance
http://dx.doi.org/10.5772/65105
103
[14] Doss, J. F., Jonassaint, J. C., Garrett, M. E., Ashley-Koch, A. E., Telen, M. J., and Chi, J.
T. (2016) Phase 1 study of a sulforaphane-containing broccoli sprout homogenate for
sickle cell disease. PLoS One 11, e0152895.
[15] Castro,  J.  P.,  Grune,  T.,  and  Speckmann,  B.  (2016)  The  two  faces  of  reactive
oxygen  species  (ROS)  in  adipocyte  function  and  dysfunction.  Biol  Chem  397,
709–724.
[16] Luperini, B. C., Almeida, D. C., Porto, M. P., Marcondes, J. P., Prado, R. P., Rasera, I.,
Oliveira, M. R., and Salvadori, D. M. (2015) Gene polymorphisms and increased DNA
damage in morbidly obese women. Mutat Res 776, 111–117.
[17] Fernandez-Sanchez, A., Madrigal-Santillan, E., Bautista, M., Esquivel-Soto, J., Morales-
Gonzalez, A., Esquivel-Chirino, C., Durante-Montiel, I., Sanchez-Rivera, G., Valadez-
Vega, C., and Morales-Gonzalez, J. A. (2011) Inflammation, oxidative stress, and obesity.
Int J Mol Sci 12, 3117–3132.
[18] Probst, B. L., McCauley, L., Trevino, I., Wigley, W. C., and Ferguson, D. A. (2015) cancer
cell growth is differentially affected by constitutive activation of NRF2 by KEAP1
deletion and pharmacological activation of NRF2 by the synthetic triterpenoid, RTA
405. PLoS One 10, e0135257.
[19] Furfaro, A. L., Traverso, N., Domenicotti, C., Piras, S., Moretta, L., Marinari, U. M.,
Pronzato, M. A., and Nitti, M. (2016) The Nrf2/HO-1 axis in cancer cell growth and
chemoresistance. Oxid Med Cell Longev 2016, 1958174
[20] Hintsala, H. R., Jokinen, E., Haapasaari, K. M., Moza, M., Ristimaki, A., Soini, Y.,
Koivunen, J., and Karihtala, P. (2016) Nrf2/Keap1 pathway and expression of oxidative
stress lesions 8-hydroxy-2?-deoxyguanosine and nitrotyrosine in melanoma. Anticancer
Res 36, 1497–1506.
[21] Cancer Genome Atlas Research, N. (2014) Comprehensive molecular profiling of lung
adenocarcinoma. Nature 511, 543–550.
[22] Cancer Genome Atlas Research, N. (2012) Comprehensive genomic characterization of
squamous cell lung cancers. Nature 489, 519–525.
[23] Yoh, K., Itoh, K., Enomoto, A., Hirayama, A., Yamaguchi, N., Kobayashi, M., Morito,
N., Koyama, A., Yamamoto, M., and Takahashi, S. (2001) Nrf2-deficient female mice
develop lupus-like autoimmune nephritis. Kidney Int 60, 1343–1353.
[24] Lee, J. M., Chan, K., Kan, Y. W., and Johnson, J. A. (2004) Targeted disruption of Nrf2
causes regenerative immune-mediated hemolytic anemia. Proc Natl Acad Sci U S A 101,
9751–9756.
[25] Ma, Q., Battelli, L., and Hubbs, A. F. (2006) Multiorgan autoimmune inflammation,
enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species
in mice lacking the antioxidant-activated transcription factor Nrf2. Am J Pathol 168,
1960–1974.
A Master Regulator of Oxidative Stress - The Transcription Factor Nrf2104
[26] Cho, H. Y., and Kleeberger, S. R. (2010) Nrf2 protects against airway disorders. Toxicol
Appl Pharmacol 244, 43–56.
[27] Ryoo, I. G., Ha, H., and Kwak, M. K. (2014) Inhibitory role of the KEAP1-NRF2 pathway
in TGFbeta1-stimulated renal epithelial transition to fibroblastic cells: a modulatory
effect on SMAD signaling. PLoS One 9, e93265.
[28] Ryoo, I. G., Shin, D. H., Kang, K. S., and Kwak, M. K. (2015) Involvement of Nrf2-GSH
signaling in TGFbeta1-stimulated epithelial-to-mesenchymal transition changes in rat
renal tubular cells. Arch Pharm Res 38, 272–281.
[29] Bolati, D., Shimizu, H., Yisireyili, M., Nishijima, F., and Niwa, T. (2013) Indoxyl sulfate,
a uremic toxin, downregulates renal expression of Nrf2 through activation of NF-
kappaB. BMC Nephrol 14, 56.
[30] Cho, H. Y., Jedlicka, A. E., Reddy, S. P., Kensler, T. W., Yamamoto, M., Zhang, L. Y., and
Kleeberger, S. R. (2002) Role of NRF2 in protection against hyperoxic lung injury in
mice. Am J Respir Cell Mol Biol 26, 175–182.
[31] Cho, H. Y., Reddy, S. P., Yamamoto, M., and Kleeberger, S. R. (2004) The transcription
factor NRF2 protects against pulmonary fibrosis. FASEB J 18, 1258–1260.
[32] Chan, K., and Kan, Y. W. (1999) Nrf2 is essential for protection against acute pulmonary
injury in mice. Proc Natl Acad Sci U S A 96, 12731–12736.
[33] de la Vega, M. R., Dodson, M., Gross, C., Manzour, H., Lantz, R. C., Chapman, E., Wang,
T., Black, S. M., Garcia, J. G., and Zhang, D. D. (2016) Role of Nrf2 and autophagy in
acute lung injury. Curr Pharmacol Rep 2, 91–101.
[34] Lee, J. M., Li, J., Johnson, D. A., Stein, T. D., Kraft, A. D., Calkins, M. J., Jakel, R. J., and
Johnson, J. A. (2005) Nrf2, a multi-organ protector? FASEB J 19, 1061–1066.
[35] Ramos-Gomez, M., Dolan, P. M., Itoh, K., Yamamoto, M., and Kensler, T. W. (2003)
Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and
tumor yield in mice. Carcinogenesis 24, 461–467.
[36] Shelton, P., and Jaiswal, A. K. (2013) The transcription factor NF-E2-related factor 2
(Nrf2): a protooncogene? FASEB J 27, 414–423.
[37] Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yama-
moto, M., and Motohashi, H. (2012) Nrf2 redirects glucose and glutamine into anabolic
pathways in metabolic reprogramming. Cancer Cell 22, 66–79.
[38] DeNicola, G. M., Chen, P. H., Mullarky, E., Sudderth, J. A., Hu, Z., Wu, D., Tang, H.,
Xie, Y., Asara, J. M., Huffman, K. E., Wistuba, II, Minna, J. D., DeBerardinis, R. J., and
Cantley, L. C. (2015) NRF2 regulates serine biosynthesis in non-small cell lung cancer.
Nat Genet 47, 1475–1481.
[39] Menegon, S., Columbano, A., and Giordano, S. (2016) The dual roles of NRF2 in cancer.
Trends Mol Med 22, 578–593.
Nrf2 Contributes to the Poor Prognosis and Chemoresistance
http://dx.doi.org/10.5772/65105
105
[40] Wang, X. J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng,
W., Wondrak, G. T., Wong, P. K., and Zhang, D. D. (2008) Nrf2 enhances resistance of
cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 29, 1235–
1243.
[41] Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., Kikuchi,
N., Satoh, H., Sakamoto, T., Hizawa, N., Itoh, K., and Yamamoto, M. (2009) Nrf2
enhances cell proliferation and resistance to anticancer drugs in human lung cancer.
Clin Cancer Res 15, 3423–3432.
[42] DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K.,
Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., Scrimieri, F., Winter, J. M., Hruban, R.
H., Iacobuzio-Donahue, C., Kern, S. E., Blair, I. A., and Tuveson, D. A. (2011) Oncogene-
induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature
475, 106–109.
[43] Bai, X., Chen, Y., Hou, X., Huang, M., and Jin, J. (2016) Emerging role of NRF2 in
chemoresistance by regulating drug-metabolizing enzymes and efflux transporters.
Drug Metab Rev, 1–27.
[44] Qaisiya, M., Coda Zabetta, C. D., Bellarosa, C., and Tiribelli, C. (2014) Bilirubin
mediated oxidative stress involves antioxidant response activation via Nrf2 pathway.
Cell Signal 26, 512–520.
[45] Li, J., Lee, J. M., and Johnson, J. A. (2002) Microarray analysis reveals an antioxidant
responsive element-driven gene set involved in conferring protection from an oxidative
stress-induced apoptosis in IMR-32 cells. J Biol Chem 277, 388–394.
[46] Nault, J. C., Rebouissou, S., and Zucman Rossi, J. (2015) NRF2/KEAP1 and Wnt/beta-
catenin in the multistep process of liver carcinogenesis in humans and rats. Hepatology
62, 677–679.
[47] Funes, J. M., Henderson, S., Kaufman, R., Flanagan, J. M., Robson, M., Pedley, B.,
Moncada, S., and Boshoff, C. (2014) Oncogenic transformation of mesenchymal stem
cells decreases Nrf2 expression favoring in vivo tumor growth and poorer survival.
Mol Cancer 13, 20.
[48] Maki, Y., Fujimoto, J., Lang, W., Xu, L., Behrens, C., Wistuba, II, and Kadara, H. (2015)
LAPTM4B is associated with poor prognosis in NSCLC and promotes the NRF2-
mediated stress response pathway in lung cancer cells. Sci Rep 5, 13846.
[49] Kanamori, M., Higa, T., Sonoda, Y., Murakami, S., Dodo, M., Kitamura, H., Taguchi, K.,
Shibata, T., Watanabe, M., Suzuki, H., Shibahara, I., Saito, R., Yamashita, Y., Kumabe,
T., Yamamoto, M., Motohashi, H., and Tominaga, T. (2015) Activation of the NRF2
pathway and its impact on the prognosis of anaplastic glioma patients. Neuro Oncol 17,
555–565.
A Master Regulator of Oxidative Stress - The Transcription Factor Nrf2106
[50] Ji, X., Wang, H., Zhu, J., Zhu, L., Pan, H., Li, W., Zhou, Y., Cong, Z., Yan, F., and Chen,
S. (2014) Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting
hypoxia-induced activation of HIF-1alpha. Int J Cancer 135, 574–584.
[51] Soini, Y., Eskelinen, M., Juvonen, P., Karja, V., Haapasaari, K. M., Saarela, A., and
Karihtala, P. (2014) Nuclear Nrf2 expression is related to a poor survival in pancreatic
adenocarcinoma. Pathol Res Pract 210, 35–39.
[52] Ko, H., Kim, S. J., Shim, S. H., Chang, H., and Ha, C. H. (2016) Shikonin induces the
apoptotic cell death via regulation of p53 and Nrf2 in AGS human stomach carcinoma
cells. Biomol Ther (Seoul) 2016, 1–9.
[53] Ryoo, I. G., Lee, S. H., and Kwak, M. K. (2016) Redox modulating NRF2: a potential
mediator of cancer stem cell resistance. Oxid Med Cell Longev 2016, 2428153.
[54] Hu, X. F., Yao, J., Gao, S. G., Wang, X. S., Peng, X. Q., Yang, Y. T., and Feng, X. S. (2013)
Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer. Asian Pac
J Cancer Prev 14, 5231–5235.
[55] Shibata, T., Kokubu, A., Gotoh, M., Ojima, H., Ohta, T., Yamamoto, M., and Hirohashi, S. (2008)
Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemo-
therapy in gallbladder cancer. Gastroenterology 135, 1358–1368, 1368 e1351–e1354.
[56] Hong, Y. B., Kang, H. J., Kwon, S. Y., Kim, H. J., Kwon, K. Y., Cho, C. H., Lee, J. M.,
Kallakury, B. V., and Bae, I. (2010) Nuclear factor (erythroid-derived 2)-like 2 regulates
drug resistance in pancreatic cancer cells. Pancreas 39, 463–472.
[57] Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang,
Y., Liao, Q., Li, W., Tang, Z., Tong, Q., Wang, X., Fang, F., Rojo de la Vega, M., Ouyang,
Q., Zhang, D. D., Yu, S., and Zheng, H. (2016) NRF2 activation by antioxidant antidia-
betic agents accelerates tumor metastasis. Sci Transl Med 8, 334–351.
[58] Sporn, M. B., and Liby, K. T. (2012) NRF2 and cancer: the good, the bad and the
importance of context. Nat Rev Cancer 12, 564–571.
[59] Hast, B. E., Cloer, E. W., Goldfarb, D., Li, H., Siesser, P. F., Yan, F., Walter, V., Zheng, N.,
Hayes, D. N., and Major, M. B. (2014) Cancer-derived mutations in KEAP1 impair NRF2
degradation but not ubiquitination. Cancer Res 74, 808–817.
[60] Hanada, N., Takahata, T., Zhou, Q., Ye, X., Sun, R., Itoh, J., Ishiguro, A., Kijima, H.,
Mimura, J., Itoh, K., Fukuda, S., and Saijo, Y. (2012) Methylation of the KEAP1 gene
promoter region in human colorectal cancer. BMC Cancer 12, 66.
[61] Liu, Q. L., Zhang, J., Liu, X., and Gao, J. Y. (2015) Role of growth hormone in maturation
and activation of dendritic cells via miR-200a and the Keap1/Nrf2 pathway. Cell Prolif
48, 573–581.
[62] Eades, G., Yang, M., Yao, Y., Zhang, Y., and Zhou, Q. (2011) miR-200a regulates Nrf2
activation by targeting Keap1 mRNA in breast cancer cells. J Biol Chem 286, 40725–40733.
Nrf2 Contributes to the Poor Prognosis and Chemoresistance
http://dx.doi.org/10.5772/65105
107
[63] Shi, L., Wu, L., Chen, Z., Yang, J., Chen, X., Yu, F., Zheng, F., and Lin, X. (2015) MiR-141
activates Nrf2-dependent antioxidant pathway via down-regulating the expression of
Keap1 conferring the resistance of hepatocellular carcinoma cells to 5-fluorouracil. Cell
Physiol Biochem 35, 2333–2348.
[64] Yang, M., Yao, Y., Eades, G., Zhang, Y., and Zhou, Q. (2011) MiR-28 regulates Nrf2 expression
through a Keap1-independent mechanism. Breast Cancer Res Treat 129, 983–991.
[65] Khunluck, T.,  Kukongviriyapan, V.,  Puapairoj,  A.,  Khuntikeo, N., Senggunprai,  L.,
Zeekpudsa, P., and Prawan, A. (2014) Association of NRF2 polymorphism with cholangio-
carcinoma prognosis in Thai patients. Asian Pac J Cancer Prev 15, 299–304.
[66] Ishikawa, T. (2014) Genetic polymorphism in the NRF2 gene as a prognosis marker for
cancer chemotherapy. Front Genet 5, 383
[67] Hartikainen, J. M., Tengstrom, M., Kosma, V. M., Kinnula, V. L., Mannermaa, A., and
Soini, Y. (2012) Genetic polymorphisms and protein expression of NRF2 and Sulfire-
doxin predict survival outcomes in breast cancer. Cancer Res 72, 5537–5546.
[68] Cho, H. Y., Jedlicka, A. E., Gladwell, W., Marzec, J., McCaw, Z. R., Bienstock, R. J., and
Kleeberger, S. R. (2015) Association of Nrf2 polymorphism haplotypes with acute lung
injury phenotypes in inbred strains of mice. Antioxid Redox Signal 22, 325–338.
[69] Marzec, J. M., Christie, J. D., Reddy, S. P., Jedlicka, A. E., Vuong, H., Lanken, P. N.,
Aplenc, R., Yamamoto, T., Yamamoto, M., Cho, H. Y., and Kleeberger, S. R. (2007)
Functional polymorphisms in the transcription factor NRF2 in humans increase the risk
of acute lung injury. FASEB J 21, 2237–2246.
[70] Shimoyama, Y., Mitsuda, Y., Tsuruta, Y., Hamajima, N., and Niwa, T. (2014) Polymor-
phism of Nrf2, an antioxidative gene, is associated with blood pressure and cardiovas-
cular mortality in hemodialysis patients. Int J Med Sci 11, 726–731.
[71] Villeneuve, N. F., Tian, W., Wu, T., Sun, Z., Lau, A., Chapman, E., Fang, D., and Zhang,
D. D. (2013) USP15 negatively regulates Nrf2 through deubiquitination of Keap1. Mol
Cell 51, 68–79.
[72] Arlt, A., Sebens, S., Krebs, S., Geismann, C., Grossmann, M., Kruse, M. L., Schreiber,
S., and Schafer, H. (2013) Inhibition of the Nrf2 transcription factor by the alkaloid
trigonelline renders pancreatic  cancer cells  more susceptible to apoptosis through
decreased proteasomal gene expression and proteasome activity. Oncogene 32, 4825–
4835.
[73] May, J. M. (2000) How does ascorbic acid prevent endothelial dysfunction? Free Radic
Biol Med 28, 1421–1429.
[74] Wagner, A. E., Boesch-Saadatmandi, C., Breckwoldt, D., Schrader, C., Schmelzer, C.,
Doring, F., Hashida, K., Hori, O., Matsugo, S., and Rimbach, G. (2011) Ascorbic acid
partly antagonizes resveratrol mediated heme oxygenase-1 but not paraoxonase-1
A Master Regulator of Oxidative Stress - The Transcription Factor Nrf2108
induction in cultured hepatocytes—role of the redox-regulated transcription factor
Nrf2. BMC Complement Altern Med 11, 1.
[75] Messier, E. M., Bahmed, K., Tuder, R. M., Chu, H. W., Bowler, R. P., and Kosmider, B.
(2013) Trolox contributes to Nrf2-mediated protection of human and murine primary
alveolar type II cells from injury by cigarette smoke. Cell Death Dis 4, e573
[76] Aon, M. A., Cortassa, S., and O’Rourke, B. (2010) Redox-optimized ROS balance: a
unifying hypothesis. Biochim Biophys Acta 1797, 865–877.
[77] Sun, S. Y. (2010) N-acetylcysteine, reactive oxygen species and beyond. Cancer Biol Ther
9, 109–110.
[78] Preston, T. J., Muller, W. J., and Singh, G. (2001) Scavenging of extracellular H2O2 by
catalase inhibits the proliferation of HER-2/Neu-transformed rat-1 fibroblasts through
the induction of a stress response. J Biol Chem 276, 9558–9564.
[79] Olayanju, A., Copple, I. M., Bryan, H. K., Edge, G. T., Sison, R. L., Wong, M. W., Lai, Z.
Q., Lin, Z. X., Dunn, K., Sanderson, C. M., Alghanem, A. F., Cross, M. J., Ellis, E. C.,
Ingelman-Sundberg, M., Malik, H. Z., Kitteringham, N. R., Goldring, C. E., and Park,
B. K. (2015) Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and
sensitizes mammalian cells to chemical toxicity-implications for therapeutic targeting
of Nrf2. Free Radic Biol Med 78, 202–212.
[80] Sun, X., Wang, Q., Wang, Y., Du, L., Xu, C., and Liu, Q. (2016) Brusatol enhances the
radiosensitivity of A549 cells by promoting ROS production and enhancing DNA
damage. Int J Mol Sci 17, 997–1010.
[81] Ren, D., Villeneuve, N. F., Jiang, T., Wu, T., Lau, A., Toppin, H. A., and Zhang, D. D.
(2011) Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated
defense mechanism. Proc Natl Acad Sci U S A 108, 1433–1438.
[82] Salminen, A., Kaarniranta, K., and Kauppinen, A. (2016) AMPK and HIF signaling
pathways regulate both longevity and cancer growth: the good news and the bad news
about survival mechanisms. Biogerontology 17, 655–680.
[83] Lee, S. L., Ryu, H., Son, A. R., Seo, B., Kim, J., Jung, S. Y., Song, J. Y., Hwang, S. G., and
Ahn, J. (2016) TGF-beta and hypoxia/reoxygenation promote radioresistance of A549
lung cancer cells through activation of Nrf2 and EGFR. Oxid Med Cell Longev 2016,
6823471
[84] Levonen, A. L. (2014) Activation of stress signaling pathways by oxidized and nitrated
lipids. Free Radic Biol Med 75 Suppl 1, S8
[85] Kansanen, E., Jyrkkanen, H. K., and Levonen, A. L. (2012) Activation of stress signaling
pathways by electrophilic oxidized and nitrated lipids. Free Radic Biol Med 52, 973–982.
[86] Taguchi, K., Motohashi, H., and Yamamoto, M. (2011) Molecular mechanisms of the
Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells 16, 123–140.
Nrf2 Contributes to the Poor Prognosis and Chemoresistance
http://dx.doi.org/10.5772/65105
109
[87] Miao, W., Hu, L., Scrivens, P. J., and Batist, G. (2005) Transcriptional regulation of NF-
E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic
response element signaling pathway: direct cross-talk between phase I and II drug-
metabolizing enzymes. J Biol Chem 280, 20340–20348.
[88] Yeager, R. L., Reisman, S. A., Aleksunes, L. M., and Klaassen, C. D. (2009) Introducing
the “TCDD-inducible AhR-Nrf2 gene battery”. Toxicol Sci 111, 238–246.
[89] Lu, H., Cui, W., and Klaassen, C. D. (2011) Nrf2 protects against 2,3,7,8-tetrachlorodi-
benzo-p-dioxin (TCDD)-induced oxidative injury and steatohepatitis. Toxicol Appl
Pharmacol 256, 122–135.
[90] Kalthoff, S., Ehmer, U., Freiberg, N., Manns, M. P., and Strassburg, C. P. (2010) Interac-
tion between oxidative stress sensor Nrf2 and xenobiotic-activated aryl hydrocarbon
receptor in the regulation of the human phase II detoxifying UDP-glucuronosyltrans-
ferase 1A10. J Biol Chem 285, 5993–6002.
[91] Shin, S., Wakabayashi, N., Misra, V., Biswal, S., Lee, G. H., Agoston, E. S., Yamamoto,
M., and Kensler, T. W. (2007) NRF2 modulates aryl hydrocarbon receptor signaling:
influence on adipogenesis. Mol Cell Biol 27, 7188–7197.
[92] Kim, S. J., Park, C., Han, A. L., Youn, M. J., Lee, J. H., Kim, Y., Kim, E. S., Kim, H. J., Kim,
J. K., Lee, H. K., Chung, S. Y., So, H., and Park, R. (2009) Ebselen attenuates cisplatin-
induced ROS generation through Nrf2 activation in auditory cells. Hear Res 251, 70–82.
[93] Zhang, Y., Talalay, P., Cho, C. G., and Posner, G. H. (1992) A major inducer of anticar-
cinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc
Natl Acad Sci U S A 89, 2399–2403.
[94] Wells, G. (2015) Peptide and small molecule inhibitors of the Keap1-Nrf2 protein-
protein interaction. Biochem Soc Trans 43, 674–679.
[95] Ammon, H. P., and Wahl, M. A. (1991) Pharmacology of Curcuma longa. Planta Med 57, 1–7.
[96] Talero, E., Avila-Roman, J., and Motilva, V. (2012) Chemoprevention with phytonu-
trients and microalgae products in chronic inflammation and colon cancer. Curr Pharm
Des 18, 3939–3965.
[97] Khan, S., Karmokar, A., Howells, L., Thomas, A. L., Bayliss, R., Gescher, A., and Brown,
K. (2016) Targeting cancer stem-like cells using dietary-derived agents—where are we
now? Mol Nutr Food Res 60, 1295–1309.
[98] Gao, S., Duan, X., Wang, X., Dong, D., Liu, D., Li, X., Sun, G., and Li, B. (2013) Curcumin
attenuates arsenic-induced hepatic injuries and oxidative stress in experimental mice
through activation of Nrf2 pathway, promotion of arsenic methylation and urinary
excretion. Food Chem Toxicol 59, 739–747.
[99] Balogun,  E.,  Hoque,  M.,  Gong,  P.,  Killeen,  E.,  Green,  C.  J.,  Foresti,  R.,  Alam,
J.,  and  Motterlini,  R.  (2003)  Curcumin  activates  the  haem  oxygenase-1  gene  via
A Master Regulator of Oxidative Stress - The Transcription Factor Nrf2110
regulation  of  Nrf2  and  the  antioxidant-responsive  element.  Biochem  J  371,
887–895.
[100] Bonnefont-Rousselot, D. (2016) Resveratrol and cardiovascular diseases. Nutrients 8,
250–274.
[101] Kalthoff, S., Ehmer, U., Freiberg, N., Manns, M. P., and Strassburg, C. P. (2010) Coffee
induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and
Nrf2 in liver and stomach. Gastroenterology 139, 1699–1710.
[102] Li,  M.,  Wang,  X.  F.,  Shi,  J.  J.,  Li,  Y.  P.,  Yang,  N.,  Zhai,  S.,  and Dang,  S.  S.  (2015)
Caffeic  acid phenethyl  ester  inhibits  liver fibrosis  in rats.  World J  Gastroenterol  21,
3893–3903.
[103] Huang, T. C., Chung, Y. L., Wu, M. L., and Chuang, S. M. (2011) Cinnamaldehyde
enhances Nrf2 nuclear translocation to upregulate phase II detoxifying enzyme
expression in HepG2 cells. J Agric Food Chem 59, 5164–5171.
[104] Wang, F., Pu, C., Zhou, P., Wang, P., Liang, D., Wang, Q., Hu, Y., Li, B., and Hao, X.
(2015) Cinnamaldehyde prevents endothelial dysfunction induced by high glucose by
activating Nrf2. Cell Physiol Biochem 36, 315–324.
[105] Huang,  C.  S.,  Lii,  C.  K.,  Lin,  A.  H.,  Yeh,  Y.  W.,  Yao,  H.  T.,  Li,  C.  C.,  Wang,  T.
S.,  and Chen,  H.  W.  (2013)  Protection by chrysin,  apigenin,  and luteolin  against
oxidative stress is mediated by the Nrf2-dependent up-regulation of heme oxygenase
1 and glutamate  cysteine  ligase  in  rat  primary hepatocytes.  Arch Toxicol  87,  167–
178.
[106] Miao, W., Hu, L., Kandouz, M., and Batist, G. (2003) Oltipraz is a bifunctional inducer
activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic
responsive element. Mol Pharmacol 64, 346–354.
[107] Wajda, A., Lapczuk, J.,  Grabowska, M., Slojewski, M., Laszczynska, M., Urasinska,
E.,  and Drozdzik,  M.  (2016)  Nuclear  factor  E2-related factor-2  (Nrf2)  expression
and regulation in  male  reproductive  tract.  Pharmacol  Rep  68,  101–108.
[108] Rao, J., Qian, X., Li, G., Pan, X., Zhang, C., Zhang, F., Zhai, Y., Wang, X., and Lu, L. (2015)
ATF3-mediated NRF2/HO-1 signaling regulates TLR4 innate immune responses in
mouse liver ischemia/reperfusion injury. Am J Transplant 15, 76–87.
[109] Imhoff, B. R., and Hansen, J. M. (2010) Tert-butylhydroquinone induces mitochondrial
oxidative stress causing Nrf2 activation. Cell Biol Toxicol 26, 541–551.
[110] Shi, X., Li, Y., Hu, J., and Yu, B. (2016) Tert-butylhydroquinone attenuates the ethanol-
induced apoptosis of and activates the Nrf2 antioxidant defense pathway in H9c2
cardiomyocytes. Int J Mol Med 38, 123–130.
[111] No, J. H., Kim, Y. B., and Song, Y. S. (2014) Targeting nrf2 signaling to combat chemo-
resistance. J Cancer Prev 19, 111–117.
Nrf2 Contributes to the Poor Prognosis and Chemoresistance
http://dx.doi.org/10.5772/65105
111

